Skye Bioscience Faces Securities Class Action Over Nimacimab Disclosures
No class has been certified, leaving shareholders unrepresented unless they retain counsel.
Overview
- Multiple investor-rights firms, including Bronstein, Rosen, and Levi & Korsinsky, announced filings and are soliciting Skye investors.
- The lawsuits cover purchasers of Skye securities from November 4, 2024 through October 3, 2025.
- Complaints allege Skye and certain officers overstated nimacimab’s effectiveness and its clinical, regulatory, and commercial prospects.
- Investors seeking to serve as lead plaintiff must move the court by January 16, 2026, though participation in any recovery does not require serving as lead plaintiff.
- Firms emphasize contingency-fee representation, stating investors may join without out-of-pocket costs.